Tykkään tästä vertailusta toiseen hoitotapaan ja sen mahdollisiin haittavaikutuksien vs RefluxStop. Aika merkittävästi vähemmän haittavaikutuksia esiintyy RefluxStop vs Nissen 
Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success
logo
Implantica announces publication of the landmark RefluxStop® 5-year clinical study results demonstrating excellent long-term success
Implantica AG (publ.), a medtech company at the forefront of treatment for acid reflux with its unique device RefluxStop®, a treatment field with 1 billion sufferers, announces the publication of RefluxStop’s extraordinary 5-year clinical data for food passageway-related outcomes in the prestigious journal, Surgical Endoscopy, an official journal of SAGES (American Gastrointestinal and Endoscopic Surgeons) and EAES (European Association For Endoscopic Surgery).
The 5-year study results, where the first published article is about food passageway sequelae, show remarkable outcomes in relation to standard of care, supporting a paradigm shift in treatment of acid reflux sufferers.
The 5 year and end of study results show:
97.9% of patients without any Adverse Event Dysphagia (difficulty swallowing)
97.9% of patients without any Adverse Event Odynophagia (painful swallowing)
95.7% of patients in the study with gas-bloating eliminated, improved or equivalent
100% of the study patients maintained the ability to belch or vomit
In addition to publication in Surgical Endoscopy, this study titled, “Food passageway-related sequelae in the RefluxStop prospective multicenter trial: Patient-centric outcomes of dysphagia, odynophagia, gas-bloating, and inability to belch and/or vomit at 5 years,” was the subject of a very successful SAGES 2025 (California, USA) oral presentation by Dr. med. Jörg Zehetner of Kinik Beau-Site Bern, Switzerland.
Implantica CEO and founder, Dr. Peter Forsell, says, “A few data points from a large recently published literature review on standard of care Nissen fundoplication1 are helpful to provide an indirect comparison and offer some perspective on how extraordinary the RefluxStop® 5-year results are. Nissen fundoplication at 5 years presented with: Dysphagia in 28.9%, gas bloating in 52.7%, and inability to belch and vomit in 39.8%. The difference in outcomes are of such magnitude that they support an edict to a paradigm shift in acid reflux treatment. Publication of this study marks the dawn of a new era in the surgical treatment of GERD, one in which patients will have an innovative surgical treatment available that can restore the natural function of their body with minimal food passageway-related sequelae.”
Dr. Forsell continues, “With a potential U.S. approval, pending FDA approval, in the near future, we are very excited about the opportunity to bring RefluxStop® to highly underserved GERD patients in the U.S. (where the disease affects 22-27% of the U.S. population) where RefluxStop’s unique non-encircling mechanism of action reduces side effects.”